Sevaro Health, Inc.

Sevaro operates at the intersection of virtual care, hospital software, and neurological specialty services. Its focus is narrower than broad telehealth platforms: the company concentrates on telestroke, neurohospitalist coverage, EEG interpretation, neurorehabilitation, and other neurology workflows. That specialization may support deeper clinical integration with hospitals than general-purpose virtual-care providers, while its Synapse AI platform adds scheduling, imaging, video, electronic medical record connectivity, and documentation capabilities around the clinical service. Sevaro OneCall is designed to connect emergency-department teams with virtual neurologists within 45 seconds, giving the company a response-time proposition relevant to stroke care. Nirvana Notes further targets provider workflow friction by automating documentation from phone and video interactions. The company’s competitive set includes hospital-employed neurology groups, tele-neurology specialists, and broader virtual-care vendors, but no specific peer companies are identified in the available company record. Its differentiation therefore rests primarily on specialty focus, physician-led delivery, and combining software with staffed neurological care rather than selling software alone.

Sevaro’s growth trajectory shows a transition from an early specialty-care venture into a more fully integrated virtual neurology platform. The company was founded in 2019, raised a $1.1 million Series A in February 2023, and released Synapse 2.0 with Nirvana Notes in November 2023. In 2024, partnerships with Ballad Health and Rosman Search indicated expansion through hospital relationships and broader neurology-service delivery. The April 2025 collaboration with Yale School of Medicine neurologists extended the company’s reach into stroke education, while the September 2025 $39 million Series B represented a substantial financing step-up from the prior round. Leadership additions also signal operational scaling: Jason Bond joined as CFO and SVP of Strategy in July 2025, and hiring activity has focused on finance and strategy roles, including Controller and Director of Finance positions connected to IPO readiness. The main execution question is whether the company can convert funding and hospital relationships into repeatable, scaled deployment of its clinical and AI platform.